Abstracts tagged "cyclophosphamide and outcomes"

Abstract Number: 2747 • 2017 ACR/ARHP Annual Meeting
Long Term Follow-up of Behcet’s Syndrome Patients Treated with Cyclophosphamide
Mert Gurcan¹, Sinem Nihal Esatoglu¹, Vedat Hamuryudan¹, Caner Saygin², Didem Saygin³, Serdal Ugurlu⁴, Emire Seyahi¹, Melike Melikoglu¹, Izzet Fresko¹, Sebahattin Yurdakul¹, Hasan Yazici¹ and Gulen Hatemi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Cleveland, OH, ³Internal Medicine, Department of Internal Medicine, Cleveland Clinic, Cleveland, Cleveland, OH, ⁴Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Cyclophosphamide (CYC) remains an important treatment option for Behçet’s syndrome (BS) pts with life threatening conditions such as arterial aneurysms. However, several adverse events…
Abstract Number: 2645 • 2014 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Pulse Cyclophosphamide for Neuropsychiatric Systemic Lupus Erythematosus: A Two-Centre Experience
Antonis Fanouriakis¹, Cristina Pamfil², Laura O. Damian³, Ioana Felea³, Emmanuel Mihali⁴, Ileana Filipescu², Theofanis Karageorgas⁵, Prodromos Sidiropoulos⁶, Simona Rednic², George Bertsias^6,7 and Dimitrios Boumpas^5,7,8, ¹Rheumatology, Clinical Immunology and Allergy, University of Crete, Heraklion, Greece, ²Rheumatology, University of Medicine and Pharmacy, Cluj-Napoca, Romania, ³Rheumatology, Emergency Clinical County Hospital Cluj, Cluj-Napoca, Romania, ⁴Emergency Clinical County Hospital Cluj, Cluj-Napoca, Romania, ⁵Clinical Immunology and Rheumatology, "Attikon" University Hospital of Athens, Athens, Greece, ⁶Rheumatology, Clinical Immunology, and Allergy, University of Crete, Heraklion, Greece, ⁷Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology-Hellas, Heraklion, Crete, Greece, ⁸Biomedical Research Foundation, Academy of Athens, Athens, Greece
Background/Purpose Cyclophosphamide (CYC) is often used in severe neuropsychiatric systemic lupus erythematosus. However, data on its use rely on small case series and a single…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].